Regents of the University of California’s Kite Pharma, Inc. KITE Stock Holding History

Regents of the University of California’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,850	Closed	-$422K	–	26
2015 Q4	$422K	Hold	6,850	–	–	1.31%	19
2015 Q3	$381K	Sell	6,850 -6,850	-50%	-$431K	1.19%	20
2015 Q2	$835K	Hold	13,700	–	–	2.34%	12
2015 Q1	$790K	Buy	+13,700	New	+$918K	0.8%	57

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Regents of the University of California's KITE Position: Q1 2016 in Review

Regents of the University of California sold out of Kite Pharma, Inc. (KITE) in Q1 2016, closing a stake of 6,850 shares — an estimated $422K sold.

Regents of the University of California first reported a position in KITE in Q1 2015 and held it in 4 quarters. The position peaked at $835K in Q2 2015. 171 funds tracked by Wall St. Rank hold KITE as of Q1 2016.

Regents of the University of California reported no remaining Kite Pharma, Inc. position as of Q1 2016 after selling out during the quarter.
Regents of the University of California sold 6,850 Kite Pharma, Inc. shares in Q1 2016, an estimated $422K.
Regents of the University of California first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 4 quarters.
Regents of the University of California's Kite Pharma, Inc. position peaked at $835K in Q2 2015.
171 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2016.

Based on Regents of the University of California's 13F filing for Q1 2016, filed 10 May 2016.